A state appeals court has revived more than 300 suits filed against Hoffmann-La Roche by users of the acne drug Accutane who claim the drug caused them to develop inflammatory bowel disease.

The panel overturned grants of summary judgment to Hoffmann-La Roche in 18 cases where plaintiffs began taking the drug after April 2002, when the package insert was amended to say the drug was “associated with inflammatory bowel disease.” The court said plaintiffs presented evidence that Hoffmann-La Roche’s knowledge of the drug’s harmful effects was sufficient to present a jury question as to the adequacy of the warning. A finder of fact could conclude that the company concluded internally that there was a causal effect between Accutane and bowel disease, but did not disclose that in its warning.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]